Peptid receptor radionuklid terápia neuroendokrin daganatokban

[1] Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy, Endocr Rev, 2003, 24:389-427
[2] Baum RP., Kulkarni HR and Carreras C: Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms, Semin Nucl Med, 2012, 42:190-207
[3] Krenning EP, Kwekkeboom DJ, Bakker WH et al: Somatostatin receptor scintigraphy with [111In-DTPA-DPhe1]- and [123I-Tyr3]- octreotide: The Rotterdam experience with more than 1000 patients, Eur J Nucl Med, 1993, 20:716-731,
[4] Valkema R, Pauwels S, Kvols LK et al.: Survival and response after peptide receptor radionuclide therapy with [90YDOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors, Semin Nucl Med, 2006, 36: 147-56.
[5] Waldherr C, Pless M, Maecke HR et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90YDOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941e5.
[6] Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ: Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 2007;46(6):723-34.
[7] Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S et al.: Yttrium-labelled peptides for therapy of NET, Eur J Nucl Med Mol Imaging, 2012, 39(Suppl 1):S93-102.
[8] Trogrlic M, Težak S.: Incremental value of (99m)Tc-HYNICTOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours. Nuklear – medizin, Nuclear Medicine, 2017, February 6
[9] Wong KK, Wynn EA, Myles J, et al.: Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors, Clin Nucl Med, 2011, 36:25-31.
[10] Buchmann I, Henze M, Engelbrecht S, et al.: Comparison of 68Ga- DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 2007, 34:1617-1626
[11] Prasad V, Ambrosini V, Hommann M, et al. : Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT, Eur J Nucl Med Mol Imaging, 2010, 37:67-77
[12]Imhof A, Brunner P, Marincek N, et al.: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers, J Clin Oncol, 2011, 29: 2416-23.
[13] Tóth M: A neuroendokrin tumorok kezelésének lehetőségei, LAM, 2013, 23(10–11)
[14] Kwekkeboom DJ, Bakker WH, Kam BL et al.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate, Eur J Nucl Med Mol Imaging, 2003, 30:
[15] Strosberg J, El‑Haddad G, Wolin E et al.: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, N Engl J Med, 2017, 376:125-35.
[16] Reismann P, Kender Z, Dabasi G , Sreter L, Rácz K, Igaz P: Neuroendokrin daganatok szomatosztatin receptor endoradioterapiája: hazai betegeken szerzett tapasztalatok, Orv. Hetil, 2011, 152, 392–397.
[17] Hörsch D, Ezziddin S, Haug A et al: Effectiveness and sideeffects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up European Journal of Cancer, Volume 58, May 2016, Pages 41-51
[18] Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP.: Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer, Semin Nucl Med, 2016, 46: 225-38.
[19] Brabander T, Teunissen JJ, Van Eijck CH et al.: Peptide receptor radionuclide therapy of neuroendocrine tumours, Best Pract Res Clin Endocrinol Metab, 2016, Jan; 30(1):103-14
[20] Forrer F, Uusi Jarvi H, Storch D, et al.: Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC, J Nucl Med, 2005, 46:1310
[21] Sabet A, Haslerud T, Pape U-F, et al.: Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 2014, 41:205
[22] Kratochwil C, Giesel FL, Bruchertseifer F et al.: 213Bi- DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, Eur J Nucl Med Mol Imaging, 2014, 41:2106
[23] Bison S, Haeck J, Koelewijn S et al.: Optimization of combination of peptide receptor radionuclide therapy (PRRT) and temozolomide therapy using SPECT/CT and MRI in mice, Eur J Nucl Med Mol Imaging, 40(Supp. l2):S290.
[24] Raymond E, Dahan L, Raoul J-L, et al.: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors, N Engl JMed, 2011, 364-501
[25] Yao JC, Shah MH, Ito T, et al.: Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, 2011, 364:514
[26] Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors, Proc Natl Acad Sci USA, 2006, 103:164
[27] Park J, A. Kuei A, Saab S, et al.: Yttrium-90 selective internal radiation therapy (SIRT) for the treatment of non-conventional liver tumors: an overview. Journal of Vascular and Interventional Radiology Volume 27, Issue 3, Supplement, March 2016, Pages S257
[28] Galleberg RB, Knigge U, Tiensuu E et al.: Results after Surgical Treatment of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Car – cinomas, European Journal of Surgical Oncology, 2017, S0748-7983(17)